BOV Stock Chart & Stats
€2.60
-€0.04(-1.20%)
At close: 4:00 PM EDT
€2.60
-€0.04(-1.20%)
Day’s Range― - ―
52-Week Range€1.61 - €4.14
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€110.63M
Enterprise Value€209.33
Total Cash (Recent Filing)€27.62M
Total Debt (Recent Filing)€39.63M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Nov 05, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding42,124,023
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)10.15
Price to Sales (P/S)2.79
P/FCF Ratio-16.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.60Price Target Upside115.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.23
Revenue Forecast (FY)€52.17M
Bulls Say, Bears Say
Bulls Say
Surgical Aesthetics GrowthStrong growth in the core Surgical Aesthetics segment indicates improving adoption across systems and consumables. Expansion in both international generators and domestic handpieces can enlarge the installed base and support recurring procedure-driven revenue over the next several quarters.
Product And Clinical ValidationRegulatory clearance expands AYON’s addressable procedural use, while reported clinical outcomes strengthen the platform’s credibility with surgeons and patients. Together, these developments can support product adoption, physician engagement and longer-term demand for related consumables.
Guidance And Liquidity RunwayReaffirmed revenue and margin targets provide a defined operating plan, while stated liquidity into 2028 gives management time to execute the AYON rollout and pursue growth without immediately requiring additional financing. This supports near-term strategic flexibility.
Bears Say
Persistent Cash Burn And LossesThe company still consumes cash internally and remains unprofitable, limiting its ability to fund expansion solely from operations. Continued cash burn may require tighter spending, working-capital control or external funding, reducing financial flexibility while the business scales.
Elevated LeverageDebt materially exceeds the equity base, increasing financial pressure while operating losses and negative cash flow persist. Elevated leverage can constrain investment choices, heighten sensitivity to execution setbacks and make future capital needs more difficult to manage.
OEM Revenue DeclineThe OEM segment is shrinking and management expects that decline to continue, creating a persistent headwind to consolidated growth. Greater dependence on Surgical Aesthetics places more pressure on AYON and Renuvion adoption to offset lost OEM revenue.
Apyx Medical News
BOV FAQ
What was Apyx Medical Corporation’s price range in the past 12 months?
Apyx Medical Corporation lowest stock price was €1.61 and its highest was €4.14 in the past 12 months.
What is Apyx Medical Corporation’s market cap?
Apyx Medical Corporation’s market cap is €110.63M.
When is Apyx Medical Corporation’s upcoming earnings report date?
Apyx Medical Corporation’s upcoming earnings report date is Nov 05, 2026 which is in 59 days.
How were Apyx Medical Corporation’s earnings last quarter?
Apyx Medical Corporation released its earnings results on Aug 06, 2026. The company reported -€0.061 earnings per share for the quarter, beating the consensus estimate of -€0.071 by €0.01.
Is Apyx Medical Corporation overvalued?
According to Wall Street analysts Apyx Medical Corporation’s price is currently Undervalued.
Does Apyx Medical Corporation pay dividends?
Apyx Medical Corporation does not currently pay dividends.
What is Apyx Medical Corporation’s EPS estimate?
Apyx Medical Corporation’s EPS estimate is -0.08.
How many shares outstanding does Apyx Medical Corporation have?
Apyx Medical Corporation has 42,124,023 shares outstanding.
What happened to Apyx Medical Corporation’s price movement after its last earnings report?
Apyx Medical Corporation reported an EPS of -€0.061 in its last earnings report, beating expectations of -€0.071. Following the earnings report the stock price went down -1.136%.
Which hedge fund is a major shareholder of Apyx Medical Corporation?
Currently, no hedge funds are holding shares in DE:BOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apyx Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.60 (115.28% Upside)
€5.60 (115.28% Upside)
Blogger Sentiment
Bearish
DE:BOV Sentiment 100%
Sector Average 60%
Sector Average 60%
Technicals
SMA
Negative
20 days / 200 days
Momentum
48.78%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
BOV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented solid commercial and clinical momentum: double-digit top-line growth (22% total, 28% surgical aesthetics), improved gross profit/margin and narrower operating and adjusted EBITDA losses, supported by FDA clearance for power liposuction and favorable clinical data. Offsetting risks include continued OEM decline, increased operating cash use and near-term manufacturing/cost pressures for new Power Lipo units, plus tariff-related cost uncertainty. On balance, the positive revenue and margin trends, clinical validation, product approvals and reaffirmed guidance outweigh the challenges.View all DE:BOV earnings summariesBOV Stock 12 Month Forecast
Average Price Target
€5.60
▲(115.28% Upside)